ESMO When 2 experts meet | Mammacarcinoom

Tijdens het ESMO-congres in Barcelona gaan dr. Marleen Kok van het NKI-AvL in Amsterdam en dr. Jolien Tol van het Jeroen Bosch Ziekenhuis in Den Bosch met elkaar in gesprek over het nieuws dat werd gepresenteerd op het gebied van mammacarcinoom. In het tweegesprek komen alle belangrijke studies voor zowel de vroeg stadium als de gemetastaseerde setting aan bod. 

De volgende studies komen voorbij.

• Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study
• Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
• Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study
• Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
• Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
• First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
• Trastuzumab deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
• Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+; advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINY-Breast12 primary results
• PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
•  eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)
• Effects of a high-intensity exercise intervention on recurrence and survival: The OptiTrain breast cancer trial

Bekijk hier de andere programma's van ESMO.

Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door AstraZeneca, MSD, Pierre Fabre en Roche.